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SUMMARY 
The administration of adenosine together with homocysteine 
resulted in a dose-related elevation of cerebral S-adenosyl-L- 
homocysteine without concomitant perturbation of S-adenosyl-L- 
methionine levels. The adenosine + homocysteine treatment also 
decreased the incorporation of labjle and stable methyl groups 
into brain protrjins. Brain [ HI-phosphatidyl N,N-dimethyl- 
ethanolamine and [ HI-phgsphatidylcholine were also significantly 
decreased while [ HI-phosphatidyl-N-monomethylethanolamine 
remained unchanged. The data indicate that elevated brain 
S-adenosylhomocysteine can markedly and selectively inhibit the 
in vivo methylation of brain proteins and phospholipids. 
INTRODUCTION 
In recent years AdoMet utilizing methylations have been 
recognized as important in a wide range of biological processes 
including the chemotactic response (l), vesicle exocytosis (2), 
the biosynthesis of phospholipids (3), membrane fluidity (4), and 
ligand-receptor interactions (5). As reported previously, the 
intraperitoneal (I.P.) co-administration of equimolar Ado and 
Hey elevates cerebral, hepatic, and blood levels of AdoHcy with- 
out significantly perturbing AdoMet levels (6,7). The elevated 
Abbreviations: Ado, adenosine; Hey, D,L homocysteine; AdoMet, 
S-adenosyl-L-methionine; AdoHcy, S-adenosyl-L-homocysteine; PME, 
phosphatidyl-N-monomethylethanolamine; PMME, phosphatidyl-N,N- 
dimethylethanolamine; PC, phosphatidylcholine; PMT, S-adenosyl-L- 
methionine: phosphatidylethanolamine-N-methyltransferase 
(EC 2.1.1.17); MGI, methyl group incorporation; TCA, trichloro- 
acetic acid. 
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tissue AdoHcy levels, in turn, resulted in decreased histamine-N- 
methyltransferase (EC 2.1.1.8) and catechol-O-methyltransferase 
(EC 2.1.1.6) activities as assayed in vitro, as well as in a 
decrease, in vivo, in the catabolism of brain histamine, which 
occurs solely by transmethylation to 3-methylhistamine (8,9). In 
light of the fact that the methylation of proteins and 
phospholipids may participate in and/or mediate the regulation of 
neural activity (1,5,10,11), it became of interest to determine 
the effects of elevated cerebral AdoHcy levels on these two 
processes. 
MATERIALS and METHODS 
Animals. Adult male Swiss-Webster mice (24-329) were from 
Charles River Laboratories (Portage, MI). They were fasted over- 
night prior to the experimental procedures which were conducted 
between 8:00 and 11:00 AM. 
Drug treatment and tissue collection. Mice were injected 
intraperitoneally (I.P.) with an equimolar mixture of Ado and Hey 
40 min prior to sacrifice by immersion (head first) in liquid 
nitrogen. Brains were removed, refrozen in liquid 
nitrogen, and stored at 
ragidly 
-80 C until time of assay. 
Determination of AdoMet and AdoHcy. AdoHcy and AdoMet 
disulfate di-p-toluenesulfonate were generously donated by Dr. 
Giorgio Stramentinoli (BioResearch Laboratories, Liscate, Italy). 
Amberlite CG-50 was from Accurate Chemical (Hicksville, NY) and 
Dowex 5OWi$8 (200-400 mesh), from BioRad (Richmond, CA). -AfgMet 
(methyl-[ C]) (specific activity 57 mCi/mmol) and Ado-(8-f C]) 
(specific activity 54 mCi/mmol) 
(Boston, MA). 
were14from New England Nuclear 
Radi~~~ti~~o~~~"TY4C~~-~byC]~ig~spr~~~~~~edli~~~~ L-Hey thiolactone 
chromatography as previously described (12). AdoMet and AdoHcy 
levels were determined using a modified isotope-dilution/ion 
exchange/HPLC method (7). 
In vivo protein methylation. L-(methyl-[3H])-methionine 
(specific activity, 1 Ci&mol) was from ICN Pharmaceuticals, 
Inc. (Irvine, CA) and L-([ C]OOH)-methionine (specific activity, 
60.7 mCi/mmol) was from Amersham-S 
For intraventricular (i.vt.) ( ,4~~:~o~f~~~~~~~~i,"~ig~~~ r [ 3;; 1 
methionine injections, the mice were lightly anesthetized with 
ether, a small piece of scalp removeg4for ease in identificatjon 
of the injecticn site and 2 uCi ([ C]OOH)- or 5 uCi ([ H- 
methyl])-methionine was injected into the lateral cerebral 
ventricle in 10 ul of artificial cerebrospinal fluid (Merlis 
solution) 2, 30, and 60 min prior to sacrifice. In all cases, 
animals were treated with Ado+Hcy or saline/Tween 80 (controls), 
40 min prior to sacrifice (7). Frozen brains were rapidly 
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weighed, and homogenized in 8.0 ml of ice-cold 5 mM sodium phos- 
phate buffer (pH 6.8), Protein carboxymethylation was determined 
using the method of Kim (13), modified as follows: Two ml of 
tissue homogenate was centrifuged (27,000 x g for 30 min), after 
which the pellet was washed three times with 1.0 ml of 5 mM 
phosphate buffer (pH 6.8) and once with 1.0 ml. ethanol. 
To determine the total MGI, the pellet was resuspended in 
1.0 ml of 5 mM phosphate buffer and a 0.1 ml aliquot counted in 
10 ml of ACS (a tissue solubilizer-scintillation mixture; 
Amersham-Searle, Arlington Heights, IL). To determine the stable 
MGI, the washed, resuspended pellet was centrifuged (27,000 x g 
for 20 min), and the pellet resuspended in 1.0 ml of 0.2 M sodium 
phosphate buffer (pH 7.4). The mixture was heated 
bath at 100°C for 5 min to hydrolyze methyl esters. 
in a water 
The sample 
was cooled, 5 mg of bovine serum albumin (Miles Biochemicals, 
Elkhart, IN) added as a carrier, and protein was precipitated 
with 1.0 ml of 30% TCA. After centrifuging (27,000 x g for 10 
min), the resulting precipitate was washed once with 1.0 ml of 
15% TCA, once with 1.0 ml of ethanol, suspended in 1.0 ml water, 
and 0.25 ml were counted in 10 ml ACS to obtain values for the 
stable MGI. The difference between the total (see above) and the 
stable MGI represents the labile (carboxymethylation) MGI (14). 
Protein was determined according to Lowry (15). 
In vivo phqspholipid methylation. All mice were injected 
i.vt. with (['H-methyl])-methionine followed 20 min later with 
either Ado+Hcy (500 mg/kg of each) or salige/Tween 80 (20 ml/kg) 
I.P. After sacrifice, 60 min after ([ H-methyl])-methionine, 
brains were processed as above for protein methylation. The 
first pellet was washed four times with 1.0 ml of 5 mM phosphate 
buffer (pH 6.8). To extract the phospholipids, the washed pellet 
was suspended in 2.0 ml of chloroform/methanol (2:1, v/v), the 
suspension vortexed for 60 set, centrifuged (27,000 x g for 30 
min) and the supernatant transferred to a screw-capped test tube. 
This extraction was repeated, and the 2 supernatants combined. 
The organic phase was washed twice with 2.0 ml of O.lM KC1 (in 
50% MeOH), and the aqueous (top) phase aspirated. A 0.1 ml 
aliquot was counted in 5.0 ml ACS for total phospholipid 
methylation. The identification of the radioactive phospholipids 
was by thin-layer chromatography (16,17). The chloroform phase 
was dried under a stream of nitrogen, the tubes were capped, and 
stored overnight at -2O'C. The residue was dissolved in 40 ul of 
a mixture containing 0.4 mg of each standard: L-a-phosphatidyl- 
ethanolamine, B,r-dipalmitoyl; L-a-phosphatidylethanolamine, N- 
methyl-l ,v-dipalmitoyl; L-a-phosphatidylethanolamine, N,N-di- 
methyl-B,Y-dipalmitoyl; L-a-lecithin, B,r-dipalmitoyl; purchased 
from Calbiochem-Behring Co. (La Jolla, CA), in chloroform/meth- 
anol, 2:1, by vol. and 25 ul applied to silica gel 60 plates 
(without fluorescent indicator) (EM Laboratories, Elmsford, NY). 
Plates were developed (16 cm) in chloroform/propionic acid/n- 
propyl alcohol/water (2:2:3:1, by vol.) (16,17), dried at 100°C 
for 10 min, and sprayed with iodine (1% in ethanol) for detection 
of phospholipids. After the spots were outlined with pencil, the 
plates were heated as above to remove iodine, each lane was 
divided into 1 cm strips and was scraped into scintillation vials 
containing 10 ml ACS and the radioactivity determined by the 
channels ratio method. The identity of the phospholipids was 
further confirmed in the solvent systems chloroform/methanol/7 M 
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ammonia (60:35:5, by vol.) and chloroform/methanol/water 
(65:25:4, by vol.) by one-dimensional thin-layer chromatography 
(16,17). 
Statistical analysis. Statistical differences between drug- 
treated groups and corresponding vehicle-treated animals were 
evaluated by the Student's 'It" test (two-tailed). P values less 
than 0.05 were considered not significant. 
RESULTS 
Effect of Ado+Hcy on Brain AdoMet and AdoHcy Levels, and on 
the Methylation Index. To determine the effects of Ado+Hcy on 
AdoMet and AdoHcy levels, mice were injected I.P. with Ado+Hcy 
(200 mg/kg or 500 mg/kg of each) and killed 40 min later (Table 
1) at which time brain AdoHcy levels are maximally elevated 
(6,7). AdoMet levels remained unchanged, while AdoHcy levels 
increased in a dose-dependent manner by 500% and 1920% at 200 
mg/kg and 500 mg/kg, respectively (Table 1;6,7). The methylation 
index (AdoMet/AdoHcy ratio), used as an index of transmethylation 
rates in brain tissue (18-20), was conversely, significantly 
decreased, -87% (200 mg/kg) and -96% (500 mg/kg) (Table 1). 
Effect of Ado+Hcy on Phospholipid Methylation. Figure 1 
shows that the co-administration of Ado+Hcy resulted in a signi- 
ficant decrease in the formation of [3H]-PMME (-60%) and [3H]-PC 
(-75%), these reactions being catalyzed by the same enzyme, PMT 
II. The brain levels of i3H]-PME, whose formation is catalyzed 
by a different enzyme, PMT I (16,17), remained unchanged after 
Ado+Hcy treatment. 
Effect of Ado+Hcy on Protein Methylation. Figure 2 shows a 
time related increase in both the stable (remaining after 
alkaline hydrolysis) and labile (carboxymethyl esters) MGI into 
proteins. Ado+Hcy significantly decreased stable MGI by 50% at 2 
min and by 53% at 30 min, while at 60 min there was no longer any 






































































































































































































































































































































































































































Figure 1. Effect of Ado+Hcy on Phospholipid Methylation in Mouse 
Brain. [3H] -methyl methionine (5 uCi/lO ul) was inJected into 
the lateral cerebral ventricle of mice 60 min prior to sacrifice. 
Ado+Hcy (500 r&kg of each) or saline/Tween 80 (20 ml/kg) was 
injected intraperitoneally-40 min before death. Results are 
expressed in dpm/g x 10 + S.E.M. in 5-7 mice. l Denotes a 
significant difference comparea to corresponding vehicle-treated 
controls at the 0.05 level using the Student ‘t’ test. 
Figure 2. Effect of Ado+Hcy on 
[ 3H] -methyl 
Protein Methylation in Mouse 
Brain. methionine (5 uCi/lO ul) was injected intra- 
ventricularly 2, 30 and 60 min prior to sacrifice. Ado+Hcy (500 
w/kg of each) or saline/‘lkeen 80 (20 ml/kg) was injected intra- 
peritoneally 40 min prior to death. Methyl group incorporation 
was determined as described in *Materials and Methods". Results 
are expressed in dpm/g x 10 -4 + S.E.M. in 5-7 mice. For statis- 
tical analysis, see Figure 1. - 
Furthermore, the administration of Ado+& y  significantly 
decreased labile MGI (protein carboxymethylation), by 42%, 74%, 
and 60% at 2, 30, and 60 min, respectively. 
DISCUSSION 
We have previously shown that the co-administration of 
equimolar Ado+Hcy results in elevated AdoHcy levels in mouse 
brain (6,7). We established that the methylation index (AdoMet/ 
AdoHcy) was reduced after Ado+Hcy (Table 1) supporting the idea 
that this ratio is a reflection of brain methylation activity 
(18,19), as suggested by others for several of the methyltrans- 
ferase enzymes (20), including PMT I and II (21). 
1102 
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It is well established that PC can be synthesized by two 
distinct pathways in brain: 1) the conversion of free choline to 
CDP-choline and a phosphobase transfer to form 1,2-diacylglycer- 
ate (22), or 2) the stepwise methylation of phosphatidylethanol- 
amine to PC using two AdoMet dependent methyltransferases 
(3,16,17). 
As shown in Figure 1, there appears to be little inhibition 
by Ado+Hcy of t3H]-PME formation perhaps because by 60 min 
labelling of PME may have begun to decay or because the newly 
formed AdoHcy fails to interact with and, hence inhibit PMT I. 
Since no inhibition of L3Hl-PME formation was noted after a 10 
min [3H-methyl]-methionine pulse (30 min prior to Ado+Hcy) (data 
not shown), the former option appears unlikely although further 
time studies need to be carried out to totally rule out this 
possibility. A likelier explanation is that since PMT I is an 
intrasynaptosomal enzyme (17,23), it is not accessible to the 
intact AdoHcy molecule which may be located for the most part 
extrasynaptosomally. This supposition is further borne out by 
studies which show the impermeable nature of membranes to AdoHcy 
(7,24-26). Further, the addition of AdoHcy did not alter the 
viscosity of erythrocyte membranes (4) or, by inference, PME 
levels. Kinetic studies with PMT I indicate that in vitro 
decreased PMT I activity does, in fact, occur simultaneously with 
a decrease in the methylation index (21). The inhibition by 
Ado+Hcy of t3H]-PMME and [3Hl-PC formation reflects inhibition of 
PMT II. PMT II is thought to be located on the outside of the 
synaptosomal membrane (23) and hence more readily accessible to 
external AdoHcy. PMT II also has a high affinity for AdoMet and 
an even higher affinity for AdoHcy (21,27). The present findings 
support the results of Chiang and Cantoni (28,29) who found that 
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elevated hepatic Ado&y levels inhibited hepatic [3H]-PC 
formation. Yet, since our procedure for administration of 
Ado+Hcy (as opposed to deazaadenosine administration (28,29) ) , 
insured increases in AdoHcy levels without perturbations in 
AdoMet levels and in the absence of any deaza-adenosylhomocys- 
teine, it is possible to relate PMT II inhibition directly to the 
elevated AdoHcy levels generated by the Ado+Hcy administration. 
To date there are three different enzymes known which are 
responsible for the N-methylation of either lysyl, arginyl or 
histidyl residues (referred to in this paper as stable MGI) , or 
the 0-methylation of carboxyl groups (referred to as labile MGI) 
(10130) I the latter reaction being catalyzed by protein methylase 
II (31). As shown (Figure 2), treatment with Ado+Hcy markedly 
decreased the labile MGI at all times tested and the stable MGI 
at the two earlier time points. Of interest is the positive 
correlation between the observed in vivo inhibition and in vitro 
kinetic studies. Assuming a 70% volume of distribution (32) at 
the higher dose of Ado+Hcy (500 mg/kg) , this should result in 
intracellular AdoHcy concentrations of 0.75 uM, which is well 
within the range of Ki values (6.5 x lo-’ M to 6 x lO+j M) 
determined for protein methyltransferases I-III (10,20,33). The 
in vivo inhibition of labile MGI (42-60%) (Figure 2) is within 
the expected values. The decreased methylation ratio, as 
mentioned, infers that the inhibition of stable or labile MGI is 
directly caused by the high intracellular AdoHcy levels. We do 
not find the failure of stable MGI to be reduced at 60 min as 
surprising, for all the available protein N-methylation sites may 
have become irreversibly occupied by 30 min. Another possibility 
is that the ( [ 3H-methyl] ) -methionine, administered 20 min before 
Ado+Hcy, may have methylated all sites before AdoHcy levels had 
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increased sufficiently to inhibit this process. That these 
differences in stable and labile MGI are due to incorporation of 
only the methyl group of methionine, and not of the intact 
methionine molecule, is supported by preliminary experiments in 
which there were no differences in incorporation of ([ %]OOH)- 
methionine into cerebral proteins comparing control and Ado+Hcy- 
treated mice (data not shown). 
With the recent evidence of increased protein 0-methylation 
simultaneous with increased neurosecretion in the pituitary and 
parotid glands (34,35) and in the adrenal medulla (2) , the 
ability to slow the rate of this methylation by raising 
endogenous AdoHcy levels may be of importance for modulation of 
neural activity in general. 
In addition, the demonstration of a role of the stepwise 
methylation of the membrane phospholipids in membrane fluidity 
(4) and in ligand-receptor interactions (5) again reflects the 
importance of controlling endogenous AdoHcy levels. 
The notion that AdoHcy is a neural modulator is further 
expanded by preliminary evidence from several laboratories 
including ours (unpublished observations) which shows that AdoHcy 
possesses sedative (36) as well as anticonvulsant (37) proper- 
ties. 
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